About 25 results found for searched term "Prostaglandin D2" (0.119 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M55668 | Recombinant Human PTGDS Protein (HEK293, C-6His) | Cytokines and Growth Factors |
| PGD2 Synthase; PGDS2; Prostaglandin-D2 Synthase; Prostaglandin-H2 D-Isomerase | ||
| Prostaglandin-D2 Synthase (PTGDS) belongs to the Lipocalin family of calycin superfamily. PTGDS catalyzes the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation. PTGDS is involved in a variety of CNS functions, such as sedation, REM sleep and PGE2-induced allodynia, and may have an anti-apoptotic role in oligodendrocytes. | ||
| M56309 | 13,14-Dihydro-15-keto prostaglandin D2 | Prostaglandin Receptor |
| 13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. | ||
| M58562 | Prostaglandin D2 | Prostaglandin Receptor |
| PGD2 | ||
| Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. PGD2 plays a protective role by suppressing inflammation. | ||
| M2471 | Bromfenac Sodium | COX |
| Bromfenac is a nonsteroidal anti-inflammatory compound (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. | ||
| M3881 | Tafluprost | Prostaglandin Receptor |
| Taflotan, Zioptan, AFP-168, MK2452 | ||
| Tafluprost is a fluorinated analog of prostaglandin F2-alpha and a PGF2alpha agonist that may be used in glaucoma-related studies. | ||
| M4655 | Byakangelicol | COX |
| Byakangelicol is white triol separated from Angelica dahurica, Interleukin-1 β (IL-1β) -induced release of prostaglandin E2 (PGE2) in A549 cells was inhibited by inhibiting the expression and activity of coX-2. Byakangelicol can be used to study airway inflammation. | ||
| M5929 | Prostaglandin E2 | Prostaglandin Receptor |
| Dinoprostone; PGE2 | ||
| Prostaglandin E2 is a vasodilator isolated from prostate gland secretion, working by binding and activating the prostaglandin E2 receptor. | ||
| M6436 | AMG 853 | Others |
| AMG 853 is a potent dual CRTH2 and prostaglandin D 2 (PGD 2) receptor antagonist. | ||
| M10632 | AM211 | Prostaglandin Receptor |
| AM-211; AM211 free acid | ||
| AM-211 is a novel and potent antagonist of the prostaglandin D2 receptor type 2, with IC50s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively. | ||
| M10803 | Butaprost | Prostaglandin Receptor |
| Butaprost is a selective prostaglandin E receptor (EP2) agonist for murine EP2 receptors EC50 The value is 33 nM,Ki The value is 2.4 μM. Butaprost is less active against rodents EP1, EP3 and EP4 receptors. Butaprost mitigates fibrosis by obstructing TGF-β/Smad2 signaling. | ||
| M10807 | CJ-42794 | Prostaglandin Receptor |
| CJ-042794 | ||
| CJ-42794 is a selective prostaglandin receptor EP4 antagonist that inhibits [3H]-PGE2 binding to EP4 receptors with an average pKi of 8.5 and is more than 200 times more selective than EP1, EP2 and EP3. | ||
| M10842 | KAG-308 | Prostaglandin Receptor |
| KAG-308 is an effective, selective, orallyable EP4 receptor (a subtype of prostaglandin E2 receptor) agonist that inhibits colitis, promotes tissue mucosal healing, and effectively inhibits the production of TNF-α. KAG-308 for human EP4 receptors Ki value and EC50 The values were 2.57 nM and 17 nM, respectively, which were more selective than EP1, EP2, EP3, and IP receptors. | ||
| M13722 | 15D-PGJ2 | PPAR |
| 15-Deoxy-Δ12,14-PGJ2; 15-deoxy-Δ12,14-prostaglandin J2 | ||
| 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. | ||
| M58604 | Vipoglanstat | PGE synthase |
| BI 1029539; GS-248; OX-MPI | ||
| Vipoglanstat (BI 1029539) is an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1; IC50 = ≤0.5 nM in isolated human whole blood). Vipoglanstat reduces LPS-induced increases in the influx of neutrophils and levels of cytokines in bronchoalveolar lavage fluid (BALF), as well as the expression of PTGES, the gene encoding mPGES-1, Cox2, and Icam1 in the lung parenchyma, in a human PTGES knock-in mouse model of acute lung injury when administered at a dose of 30 mg/kg. | ||
| M20536 | Setipiprant (ACT-129968, KYTH-105) | Immunology/Inflammation |
| Setipiprant(ACT-129968, KYTH-105) is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2) that that has been shown to have greater specificity for DP2 (CRTH2) than for DP1. | ||
| M22519 | Prostaglandin A2 | Metabolite/Endogenous Metabolite |
| PGA2; Medullin | ||
| Prostaglandin A2 (PGA2) is a endogenous metabolite derived from arachidonic acid, it plays a vital role in the induction of apoptosis. Prostaglandin A2 blocks the cell cycle progression of NIH 3T3 cells at the G1 and G2/M phase. Prostaglandin A2 induces p53-dependent apoptosis. | ||
| M30365 | AS604872 | Prostaglandin Receptor |
| AS604872 is an orally active, potent and selective prostaglandin F2α receptor (FP) antagonist with a Ki of 35 nM in humans, 158 nM in rats and 323 nM in mice. AS604872 inhibits contractions and delays labour. | ||
| M30391 | CAY10471 | Prostaglandin Receptor |
| TM30089 | ||
| CAY10471 (TM30089) is a potent, selective, and orally active prostaglandin D2 receptor CRTH2 antagonist. CAY10471 attenuates the progression of tubulointerstitial fibrosis and chronic contact hypersensitivity (CHS) in animal model. | ||
| M31252 | 8,11,14-Eicosatriynoic acid | Others |
| 8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. | ||
| M38966 | Saikogenin D | Prostaglandin Receptor |
| Saikogenin D activates epoxygenases that converts arachidonic acid to epoxyeicosanoids and dihydroxyeicosatrienoic acids, and the metabolites secondarily inhibit prostaglandin E2 (PGE2) production. Saikogenin D results in an elevation of [Ca2+]i due to Ca2+ release from intracellular stores. | ||
| M38967 | Thielavin B | Prostaglandin Receptor |
| Thielavin B is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin B effectively influences the prostaglandin E2 synthesis from the endoperoxide. Thielavin B is significantly effective on carrageenan-induced oedema of rats when administered intravenously. | ||
| M39793 | Thromboxane B2 | Others |
| Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation. | ||
| M50157 | DT-9081 | Prostaglandin Receptor |
| DT-9081 is a potentially best-in-class, orally active, small molecule prostaglandin EP4 receptor antagonist that reverses prostaglandin E2 (PGE2)-induced immunosuppression in certain tumors by blocking the EP4 receptor present on immune cells. | ||
| M54617 | Laflunimus | DHODH |
| HR325 | ||
| Laflunimus is an analog of the active metabolite of Leflunomide, A771726, and an orally active inhibitor of dihydroorotic acid dehydrogenase (DHODH) and prostaglandin endoperoxide synthase (PGHS). In addition, Laflunimus inhibits immunoglobulin (Ig) secretion with IC50 values of 2.5 and 2 μM for Ig M and IgG secretion, respectively. | ||
| M56312 | 15-keto-Prostaglandin F2a | Prostaglandin Receptor |
| 15-keto-Prostaglandin F2α (15-keto-PGF2α) is a metabolite of Prostaglandin F2α. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
